BARCELONA, 8 May. (EUROPA PRESS) -
The vice president of Hipra, Èlia Torroella, has underlined the effectiveness of the vaccine against Covid developed by the company and has assured that it is less reactogenic, that is to say, it has fewer effects "that are not serious but are annoying", among those that has highlighted the pain in the area of the puncture or the feeling of tiredness the following day.
"Having a less reactogenic vaccine is important for those people who may be reluctant to receive a booster dose because they have felt unwell after receiving a messenger RNA vaccine," he explained in an interview in 'La Vanguardia' this Monday collected by Europa Press.
He has detailed that the level of neutralizing antibodies 14 days after the booster dose is "similar" to that generated by the Pfizer vaccine and that protection against severe forms of the disease is maintained -- literally -- for at least six months.
Torrella explained that several European countries have expressed interest in acquiring doses of the vaccine for autumn: "They are waiting to see how the renegotiation of the European contract with Pfizer turns out."
He has hoped to recover the company's investment in the development of the vaccine, which he has said that Hipra has financed "mostly" with its resources.